These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30565417)

  • 21. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
    Shen YC; Wang HJ; Lee WC; Chen CH; Chuang YC
    Int J Clin Pract; 2020 Sep; 74(9):e13537. PubMed ID: 32438481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
    Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
    Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
    Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
    Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction.
    Liao CH; Kuo HC
    Urology; 2018 Jul; 117():115-119. PubMed ID: 29630956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
    Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
    Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities.
    Lee YK; Kuo HC
    Geriatr Gerontol Int; 2018 Sep; 18(9):1330-1333. PubMed ID: 29931793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.
    Illiano E; Finazzi Agrò E; Natale F; Balsamo R; Costantini E
    Int Urol Nephrol; 2020 Jun; 52(6):1035-1042. PubMed ID: 32086713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
    Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
    Zhao L; Wu F; Wang J; Wang Y; Peng W; Chen Y
    World J Urol; 2024 Jun; 42(1):370. PubMed ID: 38847900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overactive bladder medication: Persistence, drug switching, and reinitiation.
    Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
    Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ; Cho ST; Kuo HC; Chou EC; Hsu YC; Lee KS; Hadi F; Song Y; Sumarsono B
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
    Kinjo M; Yamaguchi T; Tambo M; Okegawa T; Fukuhara H
    Urol Int; 2019; 102(3):331-335. PubMed ID: 30799398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.